Vinge advises joint arrangers in connection with Sehlhall Fastigheter's issuance of sustainable bonds and refinancing

March 26, 2024 Banking and Finance

Vinge has advised the joint arrangers in connection with Sehlhall Fastigheter AB's (the "Company") issue of SEK 200 million senior secured sustainable bonds and in connection with the parallel early redemption of existing bonds issued by its subsidiary, Sehlhall Holding AB (the "Subsidiary").

The new bonds carry a floating interest rate of STIBOR 3M + 8,00% and are due in March 2027. The Company intends to apply for admission to trading of the new bonds on Nasdaq Stockholm's list for sustainable bonds.


The new bond issuance was subscribed through a repurchase of outstanding bonds issued in the Subsidiary and against cash consideration. The Company’s bond repurchase was effectuated partly by existing bondholders in the Subsidiary paying for the new bonds with their existing bonds and partly by way of issuing subordinated promissory notes.


Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as Joint Bookrunners. Swedbank AB (publ) also acted as Sole Structuring Advisor for the Company's sustainability framework.

Vinge's team consisted of Albert Wållgren, Arvid Weimers, Lionardo Ojeda, Felix Möller, August Ahlin and Rebecka Margolin.


Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024